CTLA4 and melanoma: Notably, high abundances of CD8 T cells, T cells and myeloid dendritic cells were significantly associated with clinical response in melanoma treated with combined anti-CTLA-4 and anti-PD-1 therapy, while in ccRCC, these cell populations showed positive correlation with response for patients treated with anti-PD-1.